全文获取类型
收费全文 | 64517篇 |
免费 | 4501篇 |
国内免费 | 1334篇 |
专业分类
耳鼻咽喉 | 1010篇 |
儿科学 | 2196篇 |
妇产科学 | 994篇 |
基础医学 | 7471篇 |
口腔科学 | 1038篇 |
临床医学 | 4919篇 |
内科学 | 11406篇 |
皮肤病学 | 1071篇 |
神经病学 | 14902篇 |
特种医学 | 1586篇 |
外国民族医学 | 10篇 |
外科学 | 5665篇 |
综合类 | 3562篇 |
现状与发展 | 3篇 |
一般理论 | 6篇 |
预防医学 | 3803篇 |
眼科学 | 1331篇 |
药学 | 4849篇 |
19篇 | |
中国医学 | 2147篇 |
肿瘤学 | 2364篇 |
出版年
2024年 | 154篇 |
2023年 | 1312篇 |
2022年 | 2345篇 |
2021年 | 3500篇 |
2020年 | 3138篇 |
2019年 | 4028篇 |
2018年 | 3792篇 |
2017年 | 3006篇 |
2016年 | 2285篇 |
2015年 | 2228篇 |
2014年 | 4772篇 |
2013年 | 6232篇 |
2012年 | 3917篇 |
2011年 | 3714篇 |
2010年 | 2867篇 |
2009年 | 2657篇 |
2008年 | 2472篇 |
2007年 | 1968篇 |
2006年 | 1619篇 |
2005年 | 1321篇 |
2004年 | 1347篇 |
2003年 | 1157篇 |
2002年 | 889篇 |
2001年 | 726篇 |
2000年 | 705篇 |
1999年 | 583篇 |
1998年 | 507篇 |
1997年 | 532篇 |
1996年 | 367篇 |
1995年 | 277篇 |
1994年 | 273篇 |
1993年 | 242篇 |
1992年 | 177篇 |
1991年 | 176篇 |
1990年 | 147篇 |
1989年 | 122篇 |
1988年 | 104篇 |
1985年 | 605篇 |
1984年 | 642篇 |
1983年 | 412篇 |
1982年 | 493篇 |
1981年 | 427篇 |
1980年 | 342篇 |
1979年 | 331篇 |
1978年 | 274篇 |
1977年 | 215篇 |
1976年 | 207篇 |
1975年 | 232篇 |
1974年 | 168篇 |
1973年 | 174篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
21.
AimsThe effect of Origanum majorana tea consumption on motor and non-motor symptoms was investigated in patients with idiopathic Parkinson's disease, measured by validated tools.MethodsSixty patients with idiopathic Parkinson's disease and under conventional medication were enrolled voluntarily in the study. All participants were randomized on double-blind to placebo or Origanum majorana. Clinical assessment with validated tools (UPDRSIII, NMSS, and BDI) was done before Origanum majorana or placebo consumption (Day 0) and at the end of the experiment (Day 30).ResultsThe treatment groups were similar at baseline on demographic and clinical variables. During the course of study, nine participants withdrew for reasons of noncompliance and inability to follow-up. Fifty-one participants completed the study. Upon completion of 30 days of treatment, Origanum majorana tea consumption did not decrease the UPDRSIII score ([UPDRSIII] D0 = 18.76 ± 8.58, D30 = 16.52 ± 7.96, p = 0.069) at the p value was 0.07. However, a statistically significant improvement was noted in NMSS and BDI scores (p < 0.0001 and p < 0.0001, respectively). Assessment of the UPDRSIII, NMSS and BDI scores of the patients did not reflect any improvement with placebo. No side effect was detected during the study.ConclusionThese findings show improvement of depressive and non-motor signs in patients with Parkinson's disease in the group that consumed Origanum majorana tea in combination with conventional therapy. Improvement of motor signs may need an extended treatment period. However, more research with a large number of participants and lasting longer than 1 month is needed to argue these findings. 相似文献
22.
23.
24.
《Clinical neurophysiology》2020,131(7):1444-1452
ObjectiveTo investigate cognitive functions in non-demented patients with early-onset Parkinson's disease (PD), and to compare PARK2 gene mutation carriers and non-carriers by means of event-related brain potentials (ERPs).MethodsThe participants comprised patients with early-onset PD (EOPD) and healthy controls (HC). Patients with EOPD were divided into two groups as carriers of known pathogenic variants of PARK2 gene (EOPD-PC) and non-carriers of genes involved in familial PD (EOPD-NC). ERP data were collected during auditory oddball and visual continuous performance test (CPT).ResultsBoth EOPD groups (EOPD-PC and EOPD-NC) displayed reduced and delayed P3 in response to oddball target and CPT NoGo. CPT Go P3 was reduced in EOPD-NC but not in EOPD-PC. Oddball target N1 was reduced and P2 was enhanced in both EOPD-PC and EOPD-NC. In both cognitive tasks, RTs were prolonged and accuracy was lower in EOPD-PC and EOPD-NC.ConclusionsWe found several EOPD-related neurophysiologic changes, implying impairments in cognitive functions. Pairwise comparisons between EOPD-PC and EOPD-NC revealed no significant ERP marker.SignificanceIn this study, the confounding effect of normative aging was somewhat excluded compared with many previous studies. In contrast with the many oddball studies in non-demented PD, we clearly observed reduced and prolonged P3 in early-onset PD. Our NoGo P3 findings also contribute to the limited ERP research concerning response inhibition. 相似文献
25.
26.
27.
Michelle E. Wilson Charles Kim Jacqueline Carrasco 《Orbit (Amsterdam, Netherlands)》2016,35(5):288-291
A 48-year-old smoker with a history of hyperthyroidism treated 10 years prior to presentation with radioactive iodine ablation of the thyroid gland presented to his ophthalmologist with a 2-week history of transient loss of vision in the right eye occurring for 1 to 2 hours each morning. He denied ocular pain, diplopia or change in the prominence of one or both eyes. Examination revealed 2 mm of relative proptosis on the right, bilateral temporal flare and lower lid retraction. There was minimal upper lid retraction and no evidence of lid lag. Ocular motility was full. Dilated fundoscopic examination revealed bilateral optic nerve edema, right more than left. CT of the orbit demonstrated enlargement of the extraocular muscles bilaterally with marked enlargement of the right medial rectus and left inferior rectus muscles resulting in crowding at the orbital apex bilaterally. Laboratory testing revealed the patient to be hyperthyroid. The patient was treated with high dose oral steroids followed by orbital radiation. Hyperthyroidism was managed by the patient’s primary care physician. Visual symptoms rapidly improved with oral steroids and orbital radiation. Optic nerve edema completely resolved. Repeat CT imaging demonstrated a reduction in the enlargement of the extraocular muscles with relief of bilateral optic nerve compression. 相似文献
28.
29.
Harit Kapoor Kush Raj Lohani Tommy H. Lee Devendra K. Agrawal Sumeet K. Mittal 《CTS Clinical and Translational Science》2015,8(6):841-847
Esophageal adenocarcinoma is the fastest rising cancer in the United States. It develops from long‐standing gastroesophageal reflux disease which affects >20% of the general population. It carries a very poor prognosis with 5‐year survival <20%. The disease is known to sequentially progress from reflux esophagitis to a metaplastic precursor, Barrett''s esophagus and then onto dysplasia and esophageal adenocarcinoma. However, only few patients with reflux develop Barrett''s esophagus and only a minority of these turn malignant. The reason for this heterogeneity in clinical progression is unknown. To improve patient management, molecular changes which facilitate disease progression must be identified. Animal models can provide a comprehensive functional and anatomic platform for such a study. Rats and mice have been the most widely studied but disease homology with humans has been questioned. No animal model naturally simulates the inflammation to adenocarcinoma progression as in humans, with all models requiring surgical bypass or destruction of existing antireflux mechanisms. Valuable properties of individual models could be utilized to holistically evaluate disease progression. In this review paper, we critically examined the current animal models of Barrett''s esophagus, their differences and homologies with human disease and how they have shaped our current understanding of Barrett''s carcinogenesis. 相似文献
30.